FDA traditional approval
E125382
FDA traditional approval is the U.S. Food and Drug Administration’s standard, full marketing authorization pathway granted when a drug has demonstrated substantial evidence of safety and effectiveness through adequate and well-controlled studies.
All labels observed (1)
| Label | Occurrences |
|---|---|
| FDA traditional approval canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T1103709 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: FDA traditional approval Context triple: [Leqembi, hasRegulatoryPathway, FDA traditional approval]
-
A.
Food and Drug Administration
The Food and Drug Administration is a U.S. federal agency responsible for protecting public health by regulating food, drugs, medical devices, and other consumer products.
-
B.
Federal Food, Drug, and Cosmetic Act
The Federal Food, Drug, and Cosmetic Act is a key U.S. law that authorizes the Food and Drug Administration to regulate the safety, labeling, and marketing of food, drugs, medical devices, and cosmetics.
-
C.
Center for Drug Evaluation and Research
The Center for Drug Evaluation and Research is the U.S. FDA division responsible for overseeing the safety, effectiveness, and quality of prescription and over-the-counter drugs.
-
D.
Center for Biologics Evaluation and Research
The Center for Biologics Evaluation and Research is the U.S. regulatory body responsible for overseeing the safety, efficacy, and quality of biological products such as vaccines, blood products, and gene therapies.
-
E.
Office of Regulatory Affairs
The Office of Regulatory Affairs is the U.S. FDA’s primary field organization responsible for inspecting regulated products and manufacturers, enforcing compliance, and overseeing import operations to protect public health.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: FDA traditional approval Target entity description: FDA traditional approval is the U.S. Food and Drug Administration’s standard, full marketing authorization pathway granted when a drug has demonstrated substantial evidence of safety and effectiveness through adequate and well-controlled studies.
-
A.
Food and Drug Administration
The Food and Drug Administration is a U.S. federal agency responsible for protecting public health by regulating food, drugs, medical devices, and other consumer products.
-
B.
Federal Food, Drug, and Cosmetic Act
The Federal Food, Drug, and Cosmetic Act is a key U.S. law that authorizes the Food and Drug Administration to regulate the safety, labeling, and marketing of food, drugs, medical devices, and cosmetics.
-
C.
Center for Drug Evaluation and Research
The Center for Drug Evaluation and Research is the U.S. FDA division responsible for overseeing the safety, effectiveness, and quality of prescription and over-the-counter drugs.
-
D.
Center for Biologics Evaluation and Research
The Center for Biologics Evaluation and Research is the U.S. regulatory body responsible for overseeing the safety, efficacy, and quality of biological products such as vaccines, blood products, and gene therapies.
-
E.
Office of Regulatory Affairs
The Office of Regulatory Affairs is the U.S. FDA’s primary field organization responsible for inspecting regulated products and manufacturers, enforcing compliance, and overseeing import operations to protect public health.
- F. None of above. chosen
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
FDA marketing authorization pathway
ⓘ
drug regulatory approval pathway ⓘ |
| appliesTo |
biologic products
ⓘ
human prescription drugs ⓘ new indications for approved drugs ⓘ new molecular entities ⓘ |
| canBeCombinedWith |
breakthrough therapy designation
ⓘ
fast track designation ⓘ priority review designation ⓘ |
| contrastedWith |
FDA accelerated approval
ⓘ
FDA conditional approval concepts in other jurisdictions ⓘ |
| country |
United States
ⓘ
linked to:
United States of America
|
| distinctFrom |
emergency use authorization
ⓘ
expanded access use ⓘ |
| evidenceStandard |
benefit-risk assessment favorable to patient population
ⓘ
demonstration of clinical benefit ⓘ substantial evidence from adequate and well-controlled investigations ⓘ |
| grantedBy |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
| includes |
inspection of manufacturing facilities
ⓘ
review of chemistry, manufacturing, and controls data ⓘ review of clinical efficacy data ⓘ review of clinical pharmacology data ⓘ review of clinical safety data ⓘ review of nonclinical pharmacology and toxicology data ⓘ review of proposed labeling ⓘ |
| legalBasis |
21 CFR Part 314
ⓘ
21 CFR Part 601 ⓘ 21 U.S.C. §355 ⓘ Federal Food, Drug, and Cosmetic Act ⓘ |
| mayInclude |
postmarketing commitments
ⓘ
postmarketing requirements ⓘ risk evaluation and mitigation strategy ⓘ |
| regulatoryOutcome |
full marketing authorization
ⓘ
inclusion of full prescribing information in labeling ⓘ permission to market drug in the United States ⓘ unrestricted duration of approval unless safety or efficacy concerns arise ⓘ |
| requires |
adequate and well-controlled studies
ⓘ
clinical trials demonstrating clinical benefit ⓘ statistically significant evidence from clinical trials ⓘ substantial evidence of effectiveness ⓘ substantial evidence of safety ⓘ sufficient safety database ⓘ |
| reviewedBy |
FDA Center for Biologics Evaluation and Research
ⓘ
linked to:
Center for Biologics Evaluation and Research
FDA Center for Drug Evaluation and Research ⓘ
linked to:
Center for Drug Evaluation and Research
|
| submissionType |
biologics license application
ⓘ
new drug application ⓘ |
| timeframe | standard review timeline unless priority review granted ⓘ |
| usedFor |
drugs for serious or life-threatening conditions when full evidence is available
ⓘ
drugs treating common diseases ⓘ drugs treating rare diseases ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: FDA traditional approval Description of subject: FDA traditional approval is the U.S. Food and Drug Administration’s standard, full marketing authorization pathway granted when a drug has demonstrated substantial evidence of safety and effectiveness through adequate and well-controlled studies.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.